收购交易概述 - Illumina宣布以3.5亿美元现金收购SomaLogic，并可能支付高达7500万美元的短期绩效里程碑款项和基于绩效的特许权使用费[1] - 交易还包括SomaLogic的特定资产，如位于科罗拉多州博尔德的CLIA和CAP认证实验室、办公室和制造空间[4] - 交易预计在2026年上半年完成，需满足常规交割条件，包括获得必要的监管批准[6] 战略意义 - 收购将增强Illumina在快速增长的蛋白质组学市场的地位，推进其2024年宣布的多组学战略[2] - 结合SomaLogic的蛋白质组学技术和Illumina的高通量测序平台，将加速蛋白质组学技术发展路线图，降低研究时间和成本[2] - 交易将为Illumina增加高利润率的基于NGS的试剂盒业务收入流，预计该业务将在2027年实现非GAAP营业利润，2028年营业利润率与Illumina持平[5] 技术合作与产品 - Illumina和SomaLogic自2021年12月起就SomaScan蛋白质组学检测在Illumina高通量测序平台上的应用进行合作开发[2] - Illumina Protein Prep目前已被全球近40家早期试用客户使用，将于2025年第三季度向所有客户开放[2] - SomaLogic的技术在多重性、可扩展性和技术可重复性方面表现强劲，研究人员可以在单次实验中获得高灵敏度、高通量和数千种蛋白质标记物的关键见解[3] 公司运营 - SomaLogic在全球拥有约250名员工，从事商业、研发、实验室运营、制造等工作[4] - Illumina承诺保持开放的NGS平台，维持现有蛋白质组学合作伙伴关系，并继续发展测序生态系统[3] 财务顾问 - Goldman Sachs担任Illumina的财务顾问，Cravath, Swaine & Moore担任法律顾问[7] - Centerview Partners担任Standard BioTools的财务顾问，Freshfields和Richards, Layton & Finger担任法律顾问[7] - UBS Investment Bank担任Standard BioTools董事会特别委员会的财务顾问[7]

Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business Simplifies Operating Structure and Enables Achievement of Adjusted EBITDA Break-Even Cash & Cash Equivalents of At Least $550 Million Expected at Close to Fuel Inorganic Growth Strategy and Drive Long-Term Value Creation SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Stan ...

导读： 2024年跨国仪器企业在华营收普遍下滑，仅默克实现增长，多家企业连续两年下降，受中美贸易摩擦、经济环境及市场竞争等多重因素影响。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 过去十余年间，作为全球最活跃的新兴市场，中国市场对全球科学仪器市场的影响力逐年攀升。回顾过去数年跨国企业在华业绩，可谓节节攀 升，在华营收已成为众多跨国仪器企业全球业绩的核心支撑。 0 2 4年，受中美贸易战、经济环境、市场供需等多重因素影响，全球科学仪器行业面临更多挑战。仪器信息网特别梳理了2 0 2 2 - 2 0 2 4年跨国企业 在华业绩情况，聚焦重重挑战下外企在华的机遇与挑战。 | | | | 2022-2024年跨国企业在华业绩排行榜 (单位:亿美元) | | | | | --- | --- | --- | --- | --- | --- | --- | | 序号 | 仪器公司 | 2024在华营收 | 同比变化 | 2023在华营收 | 同比变化 | 2022在华营收 | | 01 | 丹纳赫 | 28.05 | 49-10.8% | 0 31 ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and Illumina (ILMN) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts ...

SAN DIEGO, June 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), aligned with its commitments to advance the power of genomics, today published its annual Corporate Social Responsibility (CSR) Report. The report spotlights the ways Illumina is making precision health more accessible than ever before, and its ongoing work to empower people and communities, embed sustainability across its business, operate responsibly, and lead with integrity. Illumina today launched its 2024 CSR Report highlighting ...

Illumina Inc. (ILMN) recently introduced PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. PromoterAI turns data into insights to help researchers accelerate new breakthroughs in diagnosis for rare diseases. It is the latest addition to the company’s artificial intelligence ("AI") and software portfolio. ILMN Stock’s Likely Trend Following the NewsSince the announcement on May 29, ILMN’s shares declined 0.2%, closing ...

New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first timeSAN DIEGO, May 29, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. A study published today in Science illustrates how this deep learning technology discovered regulatory variants in noncoding "promoter" s ...

公司高管背景 - Jacob Thaysen于2023年加入Illumina担任CEO [2] - 此前在Agilent担任生命科学与应用市场集团及诊断与基因组学集团总裁 [2] - 更早前在Dako担任研发企业副总裁 拥有16年以上行业经验 [5] 会议开场信息 - 会议为Bernstein第41届年度战略决策会议 时间为2025年5月28日 [1] - 主持人Eve Burstein负责美国生命科学工具与诊断领域研究 [1] - 采用Pigeonhole应用收集参会者实时提问 [9] 管理层访谈重点 - 新任CEO履职已超一年 被问及任内主要成就与公司变革 [11]

Illumina (ILMN) FY 2025 Conference May 28, 2025 02:30 PM ET Speaker0 All right, thank you so much everyone for joining. Let's go ahead and get started. My name is Eve Burstein, no relation to Bernstein of Bernstein Research. I cover U. S. Life Science tools and diagnostics and it's my pleasure to have Jacob Tyson from Illumina with us today. Jacob, let me make sure we got this right, so joined Illumina as CEO in 2023 and previously served as the president of both the Life Science and Applied Markets Group a ...

Illumina, Inc. (ILMN) has received approval from Japan’s Ministry of Health, Labour and Welfare for TruSightTM Oncology (TSO) Comprehensive for Class III/IV Medical Device (Specially Controlled Medical Device). As genomic insights continue to drive breakthroughs in cancer treatment, the test is designed to make precision oncology more accessible to oncologists and patients.The latest development bolsters the company’s oncology portfolio. Illumina also stated that its clinical oncology offerings will be feat ...